Surface Plasmon Resonance (SPR) Biosensor- Biacore T200

表面等离子共振 (SPR) 生物传感器 - Biacore T200

基本信息

批准号：
8247405
负责人：
YOUSEF AL-ABED
金额：
$ 36.68万
依托单位：
FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-05-07 至 2013-05-06
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8247405
关键词：
Affinity Agonist Alzheimer&apos s Disease Antibody Affinity Area Autoimmune Process Basic Science Binding Binding Proteins Biosensor Clinical Clinical Research DNA Development Diagnostic Disease Enzyme-Linked Immunosorbent Assay Fluorescence Polarization Funding Health system Inflammatory Institutes Kinetics Laboratories Lead Long Island Malignant Neoplasms Medical Research Neurodegenerative Disorders New York PTPRC gene Pathway interactions Pharmaceutical Chemistry Property Proteins Research Research Personnel Rheumatoid Arthritis Running Scientist Screening procedure Sepsis Surface Plasmon Resonance System Systemic Lupus Erythematosus Techniques Technology Therapeutic Time Management Translating United States National Institutes of Health Work assay development cost effectiveness drug discovery human disease innovation instrument metropolitan novel novel therapeutics protein protein interaction public health relevance research and development research facility small molecule translational study yeast two hybrid system

项目摘要

DESCRIPTION (provided by applicant): The Feinstein Institute for Medical Research is a growing non-profit research center affiliated with the North Shore-LIJ Health System in Long Island, NY. Investigators at the Institute received approximately 46.7 million in the last fiscal year in NIH funding, making it among one of the major research facilities in the New York metropolitan area. Much of the research at the Feinstein is highly focused on clinical disease and the development of innovative therapeutic strategies and novel therapeutics in autoimmune, inflammatory, and neurodegenerative disease. The Biacore T200 surface plasmon resonance biosensor would be an especially important addition for the Institute which has a clear focus on translational studies and novel therapeutics. The Institute boasts a Laboratory of Medicinal Chemistry, run by Dr. Yousef Al-Abed. The Medicinal Chemistry laboratory works with several investigators to identify small molecules with diagnostic or agonist/antagonist properties directed to highly specific targets in pathways of importance in human disease. Currently, proposed surface plasmon resonance (SPR) projects include searching for lead compounds to targets in rheumatoid arthritis, systemic lupus erythematosus, Alzheimer's disease, sepsis and cancer. Analysis of binding affinities and kinetics (KD's and Kd's) during compound screening will allow optimization of these drug discovery efforts. Other investigators hope to use the instrument to study antibody affinity to DNA or protein, and protein/protein interactions. This technology allows for highly quantitative analysis of binding along with the possibility to recover novel binding proteins for subsequent identification and characterization, extending techniques such as ELISA, fluorescence polarization, and yeast two-hybrid systems. The micro-scale and automated set-up of the system also makes it extremely versatile. We are confident that acquisition of this technology will facilitate the research of numerous scientists at the Institute and allow them to work in a more proficient manner in terms of assay development and troubleshooting, time management, and cost- effectiveness. Public Health Relevance: A major focus of the Feinstein Institute for Medical Research is to translate discoveries in the basic sciences into new therapies for human disease. The Biacore T200 biosensor is an instrument that will serve to advance the understanding of molecular interactions important in human disease and also to screen therapeutic compounds which may agonize or antagonize those interactions. The Institute prides itself in the discovery of novel disease targets, originating either on the bench or from clinical research, and the development of innovative diagnostics, treatments and therapies which may one day help to alleviate human disease.

描述（由申请人提供）：Feinstein医学研究所是一个不断增长的非营利性研究中心，隶属于纽约州长岛的北岸Lij卫生系统。该研究所的调查人员在上一个财政年度的NIH资金中获得了约4670万，使其成为纽约大都会地区的主要研究机构之一。 Feinstein的大部分研究都高度关注临床疾病，以及在自身免疫性，炎症和神经退行性疾病中创新的治疗策略和新型治疗方法的发展。 Biacore T200表面等离子体共振生物传感器对于该研究所来说是一个特别重要的补充，该研究所清楚地关注翻译研究和新型治疗剂。该研究所拥有由Yousef Al-abed博士经营的药物化学实验室。药物化学实验室与几位研究人员合作，以鉴定具有诊断或激动剂/拮抗剂特性的小分子，该特性针对人类疾病重要性的高度特定靶标。目前，拟议的表面等离子体共振（SPR）项目包括寻找针对类风湿关节炎，全身性红斑狼疮，阿尔茨海默氏病，败血症和癌症靶标的铅化合物。在复合筛选过程中对结合亲和力（KD和KD）的分析将允许对这些药物发现工作进行优化。其他研究人员希望使用该仪器研究对DNA或蛋白质的抗体亲和力，以及蛋白质/蛋白质相互作用。这项技术允许对结合进行高度定量的分析，以及恢复新型结合蛋白的可能性，以进行随后的鉴定和表征，扩展了ELISA，荧光极化和酵母两杂交系统等技术。系统的微尺度和自动设置也使其非常通用。我们相信，对这项技术的收购将促进研究所的众多科学家的研究，并使他们能够在测定开发和故障排除，时间管理和成本效益方面以更熟练的方式工作。公共卫生相关性：Feinstein医学研究所的主要重点是将基本科学的发现转化为新的人类疾病疗法。 BIACORE T200生物传感器是一种仪器，可以提高对人类疾病中重要的分子相互作用的理解，并筛选可能刺激或拮抗这些相互作用的治疗化合物。该研究所以发现新型疾病靶标而引以为傲的，源于板凳或临床研究，以及创新诊断，治疗和疗法的发展，这可能有一天有助于减轻人类疾病。